Ann: Appendix 4E and Annual Report 2022, page-18

Beacon treats the underlying metabolic process of EPP. Scenesse merely provides a fake tan to reduce UV exposure.

About Bitopertin

Bitopertin is a clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. The safety profile and effects of bitopertin on heme biosynthesis were previously established in a comprehensive clinical program comprising over 4,000 individuals across multiple clinical studies. Disc Medicine is planning to develop bitopertin as a potential treatment for a range of hematologic diseases beginning with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). In preclinical models of EPP and XLP, bitopertin was shown to significantly decrease PPIX, a toxic intermediate of heme biosynthesis and which is the underlying cause of the disease.
https://www.discmedicine.com/news/disc-medicine-initiates-beacon-a-phase-2-clinical-study-of-bitopertin-in-patients-with-erythropoietic-protoporphyria-epp-and-x-linked-protoporphyria-xlp/